Laboratory Lab results are too important to go anywhere else.

Myelin Oligodendrocyte Glycoprotein Fluorescence-Activated Cell Sorting (FACS) Assay

MOG, ADEM antibody, MOG-IgG, NMO antibody, Optic Neuritis Antibody, Transverse Myelitis Antibody, Vision Loss Antibody

Test Codes

EPIC: LAB8548, Beaker: XMOGFS, Mayo: MOGFS

Department

Send Outs

Instructions

Patient Preparation: For optimal antibody detection, we recommend drawing the specimen before initiation of immunosuppressant medication.

Specimen Collection Criteria

Collect: One plain Red-top tube.

Physician Office/Draw Specimen Preparation

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to a plastic transport tube and refrigerate (2-8°C or 36-46°F).

Preparation for Courier Transport

Transport: 2.0 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 1.0 mL)

Rejection Criteria

• Grossly hemolyzed specimen
• Grossly icteric specimen
• Grossly lipemic specimen
• Specimens not collected and processed as indicated.

In-Lab Processing

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to a plastic transport tube and refrigerate (2-8°C or 36-46°F).

Transport: 2.0 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 1.0 mL)

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 72 hours
Refrigerated (2-8°C or 36-46°F): 28 days
Frozen (-20°C/-4°F or below): 28 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to Mayo Medical Laboratories, Rochester, MN.

Performed

Monday, Tuesday, Thursday. 
Results available 5-8 days.

Reference Range

Negative.

Test Methodology

Flow Cytometry

Interpretation

A positive value for myelin oligodendrocyte glycoprotein (MOG)-IgG is consistent with an neuromyelitis optica (NMO)-like phenotype, and in the setting of acute disseminated encephalomyelitis (ADEM), optic neuritis and transverse myelitis indicates an autoimmune oligodendrogliopathy with potential for relapsing course. Identification of MOG-IgG allows distinction from MS and may justify initiation of appropriate immunosuppressive therapy (not MS disease-modifying agents) at the earliest possible time. This allows early initiation and maintenance of optimal therapy. Recommend follow-up in 3 to 6 months as persistence of MOG-IgG seropositivity predicts a relapsing course.

This autoantibody is not found in healthy subjects.

Clinical Utility

Diagnosis of inflammatory demyelinating diseases (IDD) with similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis. Diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy. Diagnosis of neuromyelitis optica (NMO). Distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease. Diagnosis of ADEM. Prediction of a relapsing disease course.

CPT Codes

86363
86363-titer (if appropriate)

Contacts

Last Updated

10/10/2023